A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs GX 188E (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Sponsors Genexine
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016.
- 13 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016.